Caedo OncologyVisit company website
Develops improved treatment options for cancer patients through unique immunotherapy opportunities.
- CD47 is a well-validated target - over expressed across many cancer types – solid and hematological
- CD47 over expression correlates with poor progression free survival and overall survival prognosis
- Addresses on cology opportunities with significant unmet medical needs.
- Breast, Lung, Prostate, Bladder, Cervical, Colo-rectal, Head & Neck, Melanoma, Glioblastoma, Lymphoma, Acute, LymphoblasticLeukemia, , Acute, MyeloidLeukemia